$1.02 Billion is the total value of BVF INC/IL's 51 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 27.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CCXI | Sell | CHEMOCENTRYX INC | $92,642,000 | -5.4% | 7,034,346 | -2.3% | 9.04% | -8.9% |
| MRUS | Buy | MERUS N V | $89,103,000 | +98.7% | 3,914,913 | +61.8% | 8.70% | +91.3% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $78,399,000 | -5.1% | 4,672,195 | -7.7% | 7.65% | -8.6% |
| CYTK | Sell | CYTOKINETICS INC | $46,072,000 | +11.8% | 5,550,890 | -3.0% | 4.50% | +7.7% |
| ARQL | Sell | ARQULE INC | $41,187,000 | -13.0% | 7,447,912 | -54.7% | 4.02% | -16.2% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $41,060,000 | -31.7% | 646,811 | -1.3% | 4.01% | -34.2% |
| KURA | Buy | KURA ONCOLOGY INC | $37,444,000 | +47.5% | 2,057,346 | +52.0% | 3.65% | +42.0% |
| MRTX | New | MIRATI THERAPEUTICS INC | $36,729,000 | – | 745,000 | +100.0% | 3.58% | – |
| CTIC | CTI BIOPHARMA CORP | $34,510,000 | +27.7% | 6,929,690 | 0.0% | 3.37% | +22.9% | |
| XNCR | Sell | XENCOR INC | $32,186,000 | +19.0% | 869,645 | -3.6% | 3.14% | +14.6% |
| XOMA | XOMA CORP DEL | $31,378,000 | +3.2% | 1,502,800 | 0.0% | 3.06% | -0.6% | |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $30,582,000 | -30.9% | 1,817,138 | -6.0% | 2.98% | -33.4% |
| INFI | Buy | INFINITY PHARMACEUTICALS INC | $29,094,000 | +41.9% | 15,232,268 | +56.0% | 2.84% | +36.6% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $27,108,000 | +10.6% | 5,346,838 | +48.8% | 2.65% | +6.5% |
| ANAB | Sell | ANAPTYSBIO INC | $23,817,000 | -40.7% | 335,265 | -13.2% | 2.32% | -42.9% |
| IONS | New | IONIS PHARMACEUTICALS INC | $23,752,000 | – | 570,000 | +100.0% | 2.32% | – |
| BLRX | BIOLINERX LTDsponsored adr | $23,521,000 | +4.0% | 25,995,575 | 0.0% | 2.30% | +0.1% | |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $23,129,000 | +124.1% | 8,503,425 | +78.8% | 2.26% | +115.8% |
| GLMD | New | GALMED PHARMACEUTICALS LTD | $20,963,000 | – | 1,761,567 | +100.0% | 2.05% | – |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $20,758,000 | -7.9% | 1,890,507 | -3.3% | 2.03% | -11.3% |
| IMDZ | Buy | IMMUNE DESIGN CORP | $18,921,000 | +39.6% | 4,158,353 | +1.3% | 1.85% | +34.4% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $17,862,000 | – | 1,129,761 | +100.0% | 1.74% | – |
| VSTM | Sell | VERASTEM INC | $15,427,000 | +89.1% | 2,242,353 | -18.1% | 1.51% | +82.1% |
| SPRO | SPERO THERAPEUTICS INC | $15,388,000 | +2.9% | 1,048,958 | 0.0% | 1.50% | -0.9% | |
| MEIP | New | MEI PHARMA INC | $12,136,000 | – | 3,080,308 | +100.0% | 1.18% | – |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $11,748,000 | -40.1% | 959,840 | -24.4% | 1.15% | -42.3% |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $11,600,000 | -86.4% | 606,715 | -89.1% | 1.13% | -86.9% |
| CDTX | New | CIDARA THERAPEUTICS INC | $10,039,000 | – | 1,930,670 | +100.0% | 0.98% | – |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $9,529,000 | +173.5% | 1,417,967 | +249.6% | 0.93% | +163.5% |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $9,470,000 | -30.0% | 4,099,589 | -3.6% | 0.92% | -32.6% |
| SBPH | Sell | SPRING BK PHARMACEUTICALS INC | $9,314,000 | -27.2% | 785,950 | -5.6% | 0.91% | -30.0% |
| RGLS | Sell | REGULUS THERAPEUTICS INC | $9,021,000 | -10.0% | 13,685,204 | -2.1% | 0.88% | -13.4% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $8,660,000 | -81.2% | 1,233,618 | -61.9% | 0.84% | -81.9% |
| VBIV | VBI VACCINES INC | $8,525,000 | -21.4% | 3,100,000 | 0.0% | 0.83% | -24.4% | |
| ALBO | Sell | ALBIREO PHARMA INC | $7,810,000 | +6.6% | 220,000 | -2.2% | 0.76% | +2.6% |
| CFRX | Sell | CONTRAFECT CORP | $7,428,000 | +33.5% | 3,361,071 | -4.0% | 0.72% | +28.5% |
| ERYP | ERYTECH PHARMAsponsored adr | $7,213,000 | -45.0% | 625,000 | 0.0% | 0.70% | -47.1% | |
| XENE | XENON PHARMACEUTICALS INC | $6,632,000 | +87.8% | 720,830 | 0.0% | 0.65% | +80.7% | |
| GTXI | Sell | GTX INC DEL | $5,912,000 | -45.4% | 386,134 | -36.7% | 0.58% | -47.4% |
| SURF | New | SURFACE ONCOLOGY INC | $5,453,000 | – | 334,333 | +100.0% | 0.53% | – |
| MACK | New | MERRIMACK PHARMACEUTICALS INC | $5,453,000 | – | 1,110,588 | +100.0% | 0.53% | – |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $4,868,000 | -10.0% | 643,059 | -4.8% | 0.48% | -13.3% |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $4,505,000 | -14.2% | 5,265,000 | +5.3% | 0.44% | -17.3% |
| TOCA | Sell | TOCAGEN INC | $4,399,000 | -26.4% | 471,007 | -6.6% | 0.43% | -29.2% |
| MTEM | MOLECULAR TEMPLATES INC | $3,602,000 | -34.6% | 688,629 | 0.0% | 0.35% | -36.9% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $3,571,000 | -22.1% | 1,684,636 | 0.0% | 0.35% | -24.8% | |
| EPIX | New | ESSA PHARMA INC | $2,090,000 | – | 552,791 | +100.0% | 0.20% | – |
| ADRO | Sell | ADURO BIOTECH INC | $2,072,000 | -72.4% | 295,965 | -63.3% | 0.20% | -73.4% |
| VICL | Sell | VICAL INC | $1,532,000 | -25.0% | 1,332,605 | -5.5% | 0.15% | -27.5% |
| LOXO | Sell | LOXO ONCOLOGY INC | $709,000 | +40.1% | 4,089 | -6.8% | 0.07% | +35.3% |
| ZYME | New | ZYMEWORKS INC | $293,000 | – | 19,804 | +100.0% | 0.03% | – |
| OREXQ | Exit | OREXIGEN THERAPEUTICS INC | $0 | – | -534,900 | -100.0% | -0.01% | – |
| Exit | ESSA PHARMA INC | $0 | – | -10,183,646 | -100.0% | -0.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.